Immunomodulatory Profile
Bispecifics and CAR-T sequences
Watch Video
Short educational videos
Bispecifics and CAR-T sequences
Watch Video
Human cord blood-derived hematopoietic CD34+ stem cells. Validated: greater than 25% human CD45+ cells in peripheral blood. Humanized NSG variants (hu-CD34+). Infectious disease, gene therapy, cancer,
Watch Video
Assessing efficacy and toxicity in CAR-T studies in an accessible translational model. The Jackson Laboratory's in vivo PBMC-humanized mouse platform provides a wider window to look at cytokine releas
Watch Video
The FcRn platform from The Jackson Laboratory mimics specific aspects of the human IgG physiology providing the ideal model platform to assess the pharmacokinetics (PK) of therapeutic antibody candida
Watch Video
A really important component of IgG antibodies is their ability to have a really long half-life in circulation, as opposed to other Ig subclasses. Lower pH causes the IgG antibodies, not the IgM or I
Watch Video
Immunomodulatory therapies are the latest weapon to be added to the cancer-fighting arsenal. These therapies work by generating or augmenting the immune response to a tumor. Discovering and validating
Watch Video
With The Jackson Laboratory’s novel humanized mouse models for CRS, you can test for both, immunotoxicity, and drug efficacy at the same time. You can test candidate therapies, with or without the pre
Watch Video
What is Cytokine Release Syndrome? CRS occurs when the innate and adaptive immune systems are overactivated, releasing too many cytokines, which are substances that can affect other cells.
Watch Video